Jazz Pharmaceuticals gets NICE backing for its cannabinoid-based medicine
The UK health technology assessor the National Institute for Health and Care Excellence (NICE) , has been recommended for reimbursement for USA-based Jazz Pharmaceuticals’ (Nasdaq: JAZZ) Epidyolex (cannabidiol,100mg/mL oral solution), for adjunctive therapy of seizures associated with tuberous sclerosis complex (TSC), for patients two years of age and older.
Epidyolex was originally developed by UK company GW Pharmaceuticals, which was acquired by Jazz for around $7.2 billion in early 2021.
Following earlier decisions by the Scottish Medicines Consortium, Northern Ireland’s Strategic Planning and Performance Group and the All Wales Medicines Strategy Group this recommendation now ensures all eligible UK patients who may benefit from this medicine will be able to receive reimbursed access to Epidyolex from March 1 this year, Jazz noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze